Peptide peddlers cheer as RFK Jr. unilaterally grants access, overruling FDA

Key Points:

• Health Secretary Robert F. Kennedy has issued a rule allowing specialty pharmacies to sell six specific peptide drugs, overruling FDA scientists who warn of insufficient evidence and potential dangers.
• The peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500—were removed from the FDA’s compounding pharmacy list in 2023 due to safety concerns, but Kennedy’s rule halts enforcement against their production and sale.
• Kennedy’s policy cites an FDA advisory panel vote to reinstate the peptides, but the panel was reportedly stacked with members linked to peptide businesses, raising conflict-of-interest questions.
• Supporters hail the move as advancing medical freedom and patient choice, while critics warn it risks public safety, could impede rigorous clinical trials, and may encourage the spread of unapproved, potentially harmful products.
• Consumer safety groups and medical watchdogs emphasize the lack of solid evidence on peptide safety and efficacy, urging adherence to scientific standards and caution against expanding access without proper oversight.